Answers are grounded in this paper and cite their sources.
2-Deoxy-2,2-difluoroglycosides are a new class of mechanism-based inhibitors of alpha-glycosidases, which function via the accumulation of a stable difluoroglycosyl-enzyme intermediate. Two members of this new class of inhibitor have been synthesized and kinetic studies performed with their target glycosidases. Thus 2,4,6-trinitrophenyl 2-deoxy-2,2-difluoro-alpha-glucoside is shown to inactivate yeast alpha-glucosidase with a second order rate constant of ki/Ki = 0.25 min-1 mM-1. The equivalent difluoromaltoside inactivates human pancreatic alpha-amylase with ki/Ki = 0.0073 min-1 mM-1. Competitive inhibitors protect the enzyme against inactivation in each case, showing reaction to occur at the active site. A burst of release of one equivalent of trinitrophenolate observed upon inactivation of human pancreatic alpha-amylase proves the required 1:1 stoichiometry. These are the first mechanism-based inhibitors of this class to be described, and the first mechanism-based inhibitors of any sort for the medically important alpha-amylase. In addition to having potential as therapeutics, compounds of this class should prove useful in subsequent structural and mechanistic studies of these enzymes.
No takes yet. Share an insight, caveat, or question.
Braun et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: